Clinical Results of Anti-adhesion Adjuvants after Endonasal Dacryocystorhinostomy.
- Author:
Hye Young SHIN
1
;
Ji Sun PAIK
;
Suk Woo YANG
Author Information
- Publication Type:Original Article
- Keywords: Anti-adhesion adjuvants; Endonasal dacryocystorhinostomy; HyFence; Mediclore
- MeSH: Carboxymethylcellulose Sodium; Dacryocystorhinostomy*; Follow-Up Studies; Humans; Hyaluronic Acid; Intubation; Nasal Cavity; Osteotomy; Prognosis; Retrospective Studies; Silicon; Silicones
- From:Korean Journal of Ophthalmology 2018;32(6):433-437
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Various absorbable anti-adhesion agents have been used to prevent postoperative synechia formation after endonasal surgery. The purpose of this study was to evaluate the anti-adhesion effects of HyFence and Mediclore after endonasal dacryocystorhinostomy (DCR) compared to a mixed solution of hyaluronic acid and sodium carboxymethylcellulose (Guardix-Sol). METHODS: In this retrospective study, endonasal DCR and silicone tube intubation were performed on 198 eyes of 151 patients. Three different anti-adhesion adjuvants were applied to the osteotomy site in the nasal cavity after standard endonasal DCR procedures. The subjects were classified into three respective groups: group A (71 eyes, Guardix-Sol 1.5 g), group B (89 eyes, HyFence 1.5 mL), and group C (38 eyes, Mediclore 1 cc). The three groups were evaluated by asking patients about subjective symptoms and by performing lacrimal irrigation tests and endoscopic examinations. RESULTS: There were no statistically significant differences in age, sex, timing of tube removal, or follow-up period among the three groups. There were no statistically significant differences in success rates among the three groups (p = 0.990, 91.5% [65 / 71], 92.1% [82 / 89], and 92.1% [35 / 38], respectively). CONCLUSIONS: HyFence and Mediclore are safe and effective adjunctive modalities following endonasal DCR compared to Guardix-Sol. Therefore, these agents can be considered good alternatives to Guardix-Sol to increase the success rate of endonasal DCR in treating patients with poor prognosis.
